Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Cyclerion Therapeutics (NASDAQ: CYCN) has announced participation in two upcoming investor conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will be held from September 13-15, 2021, featuring an on-demand session starting September 13 at 7:00 a.m. EDT. Additionally, the Cantor Fitzgerald Virtual Global Healthcare Conference is scheduled for September 30, 2021, at 2:40 p.m. EDT. Live webcasts can be accessed through the Investors & Media section of Cyclerion's website, with archived versions available for 90 days.

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Company management will present at two upcoming investor conferences.

• H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021. On-demand session is available starting at 7:00 a.m. EDT on September 13^th.
• Cantor Fitzgerald Virtual Global Healthcare Conference, September 30, 2021 at 2:40 p.m. EDT.

The live webcasts can be accessed via the Investors & Media section of the Cyclerion website at https://ir.cyclerion.com/news-events/event-calendar. An archived replay of the events will be available on the site for approximately 90 days following the presentations.

About Cyclerion Therapeutics

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion is advancing novel, first-in-class, CNS-penetrant, sGC stimulators that modulate a key node in a fundamental CNS signaling pathway. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases. The most advanced compound, CY6463 has shown rapid improvement in biomarkers associated with cognitive function and is currently in clinical development for Alzheimer's Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associated with Schizophrenia (CIAS). Cyclerion is also advancing CY3018, a next generation sGC stimulator.

For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).

Investors
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com

Media
Amanda Sellers
Verge Scientific Communications
asellers@vergescientific.com

FAQ

What is Cyclerion Therapeutics presenting at the investor conferences in September 2021?

Cyclerion Therapeutics will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021, and the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, 2021.

How can I access the webcasts for Cyclerion's investor presentations?

The live webcasts for Cyclerion's presentations can be accessed via the Investors & Media section of their website.

What are the dates for the H.C. Wainwright conference where Cyclerion will participate?

The H.C. Wainwright 23rd Annual Global Investment Conference is scheduled for September 13-15, 2021.

What is the stock symbol for Cyclerion Therapeutics?

The stock symbol for Cyclerion Therapeutics is CYCN.

When will Cyclerion present at the Cantor Fitzgerald Virtual Global Healthcare Conference?

Cyclerion will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, 2021, at 2:40 p.m. EDT.